TISCH

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H526033

CAS#: 131615-52-6

Description: TISCH is a potent and selective iodinated ligand for CNS D1 dopamine receptor.

Chemical Structure

img
TISCH
CAS# 131615-52-6
Instruction

Theoretical Analysis

Hodoodo Cat#: H526033
Name: TISCH
CAS#: 131615-52-6
Chemical Formula: C17H17ClINO
Exact Mass: 413.00
Molecular Weight: 413.684
Elemental Analysis: C, 49.36; H, 4.14; Cl, 8.57; I, 30.68; N, 3.39; O, 3.87

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: TISCH

IUPAC/Chemical Name: (R)-8-Chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-1H-3-benzazepin-7-ol

InChi Key: DUTJKDUWCSYNLM-OAHLLOKOSA-N

InChi Code: InChI=1S/C17H17ClINO/c1-20-6-5-12-8-16(18)17(21)9-14(12)15(10-20)11-3-2-4-13(19)7-11/h2-4,7-9,15,21H,5-6,10H2,1H3/t15-/m1/s1

SMILES Code: OC1=C(Cl)C=C2CCN(C)C[C@H](C3=CC=CC(I)=C3)C2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 413.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Smith CB, Phillips T, Smith TJ. Using the New ASCO Clinical Practice Guideline for Palliative Care Concurrent With Oncology Care Using the TEAM Approach. Am Soc Clin Oncol Educ Book. 2017;37:714-723. doi: 10.14694/EDBK_175474. PubMed PMID: 28561696.

2: Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352-z. [Epub ahead of print] PubMed PMID: 28555325.

3: Germain D. Toward the identification and the targeting of key players of the mitochondrial unfolded protein response (UPR(mt)) in cancer. J Bioenerg Biomembr. 2017 May 29. doi: 10.1007/s10863-017-9716-x. [Epub ahead of print] PubMed PMID: 28555290.

4: Molotkov A, Mazot P, Brewer JR, Cinalli RM, Soriano P. Distinct Requirements for FGFR1 and FGFR2 in Primitive Endoderm Development and Exit from Pluripotency. Dev Cell. 2017 May 23. pii: S1534-5807(17)30386-6. doi: 10.1016/j.devcel.2017.05.004. [Epub ahead of print] PubMed PMID: 28552557.

5: de Galarreta MR, Lujambio A. Therapeutic editing of hepatocyte genome in vivo. J Hepatol. 2017 May 17. pii: S0168-8278(17)32048-2. doi: 10.1016/j.jhep.2017.05.012. [Epub ahead of print] Review. PubMed PMID: 28527665.

6: Patel V, Collazo Lorduy A, Stern A, Fahmy O, Pinotti R, Galsky MD, Gakis G. Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Bladder Cancer. 2017 Apr 27;3(2):121-132. doi: 10.3233/BLC-170108. PubMed PMID: 28516157; PubMed Central PMCID: PMC5409038.

7: Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review. PubMed PMID: 28515944; PubMed Central PMCID: PMC5432988.

8: Chen S, Tisch N, Kegel M, Yerbes R, Hermann R, Hudalla H, Zuliani C, Gülcüler GS, Zwadlo K, von Engelhardt J, Ruiz de Almodóvar C, Martin-Villalba A. CNS Macrophages Control Neurovascular Development via CD95L. Cell Rep. 2017 May 16;19(7):1378-1393. doi: 10.1016/j.celrep.2017.04.056. PubMed PMID: 28514658.

9: Chakraborty R, Hampton OA, Abhyankar H, Zinn DJ, Grimes A, Skull B, Eckstein O, Mahmood N, Wheeler DA, Lopez-Terrada D, Peters TL, Hicks JM, Elghetany T, Krance R, Poulikakos PI, Merad M, McClain KL, Allen CE, Parsons DW. Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Apr 29. doi: 10.18632/oncotarget.17521. [Epub ahead of print] PubMed PMID: 28512266.

10: Dennis EL, Faskowitz J, Rashid F, Babikian T, Mink R, Babbitt C, Johnson J, Giza CC, Jahanshad N, Thompson PM, Asarnow RF. Diverging volumetric trajectories following pediatric traumatic brain injury. Neuroimage Clin. 2017 Mar 31;15:125-135. doi: 10.1016/j.nicl.2017.03.014. eCollection 2017. PubMed PMID: 28507895; PubMed Central PMCID: PMC5423316.

11: Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017 May 12. pii: S0169-409X(17)30063-7. doi: 10.1016/j.addr.2017.05.007. [Epub ahead of print] PubMed PMID: 28506744.

12: Migliaccio AR, Uversky VN. Dissecting physical structure of calreticulin, an intrinsically disordered Ca(2+)-buffering chaperone from endoplasmic reticulum. J Biomol Struct Dyn. 2017 May 26:1-20. doi: 10.1080/07391102.2017.1330224. [Epub ahead of print] PubMed PMID: 28504081.

13: Tisch M. [Implantable Hearing Devices]. Laryngorhinootologie. 2017 Apr;96(S 01):S84-S102. doi: 10.1055/s-0042-118775. Epub 2017 May 12. German. PubMed PMID: 28499296.

14: Stappler E, Dattenböck C, Tisch D, Schmoll M. Analysis of Light- and Carbon-Specific Transcriptomes Implicates a Class of G-Protein-Coupled Receptors in Cellulose Sensing. mSphere. 2017 May 10;2(3). pii: e00089-17. doi: 10.1128/mSphere.00089-17. eCollection 2017 May-Jun. PubMed PMID: 28497120; PubMed Central PMCID: PMC5425790.

15: Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2017 Apr;9(4):287-298. doi: 10.1177/1758834016687261. Epub 2017 Feb 14. Review. PubMed PMID: 28491148; PubMed Central PMCID: PMC5405995.

16: Alimohammadian M, Majidi A, Yaseri M, Ahmadi B, Islami F, Derakhshan M, Delavari A, Amani M, Feyz-Sani A, Poustchi H, Pourshams A, Sadjadi AM, Khoshnia M, Qaravi S, Abnet CC, Dawsey S, Brennan P, Kamangar F, Boffetta P, Sadjadi A, Malekzadeh R. Multimorbidity as an important issue among women: results of a gender difference investigation in a large population-based cross-sectional study in West Asia. BMJ Open. 2017 May 9;7(5):e013548. doi: 10.1136/bmjopen-2016-013548. PubMed PMID: 28490550.

17: Necchi A, Raggi D, Giannatempo P, Sonpavde G, Galsky MD, Bellmunt J, Mariani L, Miceli R. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clin Genitourin Cancer. 2017 Apr 13. pii: S1558-7673(17)30092-7. doi: 10.1016/j.clgc.2017.04.008. [Epub ahead of print] PubMed PMID: 28478885.

18: Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, Meinhof K, Chow A, Kim-Shulze S, Wolf A, Medaglia C, Li H, Rytlewski JA, Emerson RO, Solovyov A, Greenbaum BD, Sanders C, Vignali M, Beasley MB, Flores R, Gnjatic S, Pe'er D, Rahman A, Amit I, Merad M. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017 May 4;169(4):750-765.e17. doi: 10.1016/j.cell.2017.04.014. PubMed PMID: 28475900.

19: Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol. 2017 May 4. doi: 10.1007/s00535-017-1348-8. [Epub ahead of print] Erratum in: J Gastroenterol. 2017 May 29;:. PubMed PMID: 28474222.

20: Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE 2nd, Hoang JK, Yin FF, Sampson JH, Fecci PE, Blackwell KL, Kirkpatrick JP, Kim GJ. Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. Neuro Oncol. 2017 May 3. doi: 10.1093/neuonc/nox090. [Epub ahead of print] PubMed PMID: 28472527.